Where are the exceptional responders?

Hi David

Is the gist of your post that you’re trying to estimate how much stock we should put in a drug sponsor’s promise that there could someday be an “exceptional responder” to a new therapy, even if the sponsor hasn’t been able to demonstrate an exceptional response after treating “X” number of patients?

If so, then couldn’t we just invert the title of the following article from 1983, changing it from:

“If Nothing Goes Wrong, Is Everything All Right?”

https://jamanetwork.com/journals/jama/article-abstract/385438#google_vignette

to

“If Nothing Goes Right, Is Everything All Wrong?”